177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study

Trial Profile

177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs ATL 101 Telix Pharmaceuticals (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Glioma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 20 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 04 May 2015 Planned End Date changed from 1 Jul 2012 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top